INFORMACIÓN BÁSICA SOBRE COOKIES

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web.
La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias.
Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso.
En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web.
Más información en el apartado POLÍTICA DE COOKIES de nuestra página web.

ACEPTAR RECHAZAR
  • Tel. 900 101 549
  • +34 93 546 01 35
  • Facebook IOR
  • Twitter IOR
  • LinkedIn IOR
  • Hospital Universitari Dexeus
  • Centro Médico Teknon
  • Hospital Universitari General de Cataluña
  • Hospital Universitari Sagrat Cor

LIST OF CLINICAL TRIALS

Search for clinical trials open in our centers by cancer type.

PLEASE MAKE A SELECTION TO
BROWSE RESULTS

OPEN TRIAL CLOSED TRIAL

LUNG AND PLEURAL CANCER

ARIAD ALTA-1 [OPEN TRIAL]

Phase III multicenter, open label study of brigatinib (AP26113) vs. crizotinib in patients with advanced ALK-positive lung cancer. Protocol: AP26113-13-301

+ INFO

LUNG AND PLEURAL CANCER

ATALANTE1 [OPEN TRIAL]

Ramdomized, phase III clinic trial in paralel groups of OSE 2101 in second line following failure of platinum-based chemotherapy, or as third line following failure of platinum and immune control point inhibitors, compared with standard treatment (docetaxel or pemetrexed) in patients with HLA-A2 positive and metastatic or locally-advanced non-small cell lung cancer (IIIB) not eligible for radiotherapy. Protocol OSE2101C301

+ INFO

BREAST CANCER, EXPLORATORY STUDIES

AURORA PROGRAM [OPEN TRIAL]

Towards a better understanding of molecular aberrations in metastatic breast cancer. Exploratory Study.

+ INFO

LUNG AND PLEURAL CANCER

AZENT [OPEN TRIAL]

Phase IIa clinical trial of safety and efficacy of AZD9291 in treatment-naïve patients with EGFR mutated advanced non-small-cell lung cancer (NSCLC) with concommitant presence of the EGFR T790M mutation. Protocol: MedOPP112

+ INFO

LUNG AND PLEURAL CANCER

BO39694 [OPEN TRIAL]

A multicenter, international, rollover study of alectinib in patients with anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer.

+ INFO

LUNG AND PLEURAL CANCER

BV-NSCLC-002 [OPEN TRIAL]

A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R NSCLC patients eligible toreceive standard treatment and supportive care. Protocol: BV-NSCLC-002

+ INFO

LUNG AND PLEURAL CANCER

CALLISTO [OPEN TRIAL]

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer. Protocol: 54767414LUC2001

+ INFO

LUNG AND PLEURAL CANCER

CDRB436E2406 [OPEN TRIAL]

A multi-country retrospective chart review study of patients with ALK-positive, BRAF V600-positive, and cMET-positive (ABC) non-small cell lung cancer (NSCLC).

+ INFO

LUNG AND PLEURAL CANCER

CL1-49076-003 [OPEN TRIAL]

Phase I/II study of oral S49076 in combination with gefitinib in advanced non-small-cell lung cancer patients with EGFR mutations who have progressed following treatment on EGFR tyrosine kinase inhibitor. Protocol: CL1-49076-003

+ INFO

MELANOMA

CO39721 [OPEN TRIAL]

A phase ib study evaluating cobimetinib plus atezolizumab in patients with advanced brafv600 wild-type melanoma who have progressed during or after treatment with anti−pd-1 therapy.

+ INFO